techno

  Neuroblastoma is a type of cancer that forms in certain types of nerve cells (neuroblasts) found in an embryonic tissue called the neural crest. It most commonly forms in the adrenal glands, abdomen or chest. The global neuroblastoma therapeutic market is primarily driven by the increasing incidence of neuroblastoma disease globally. Neuroblastoma therapeutics occurs in around 1 in 100,000 children per year, making it one of the most common cancers in babies and young children. The primary treatment for neuroblastoma involves chemotherapy, surgery, radiation therapy, stem cell transplant and immunotherapy. Key therapeutic options include chemotherapy drugs like carboplatin, etoposide, cyclophosphamide; targeted therapies like dinutuximab and anti-GD2 antibody; and other novel drugs. The Global Neuroblastoma Therapeutic Market is estimated to be valued at US$ 2.78 Bn in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 To 2031. Key Takeaways Key pl...

  The opioid overdose treatment market provides promising treatment solutions to combat the growing problem of opioid addiction. Naloxone-based overdose reversal drugs are most commonly used to temporarily reverse the effects of opioid overdose including extreme drowsiness, slowed breathing, or loss of consciousness. Other marketed products include buprenorphine and methadone used for medication-assisted treatment of opioid use disorder. The market has seen steady demand with rising rates of prescription and illegal opioid abuse. According to the UN, around 275 million people globally use drugs, with over 35 million suffering from substance use disorders. The economic burden of the opioid crisis on the healthcare system has also fueled further investments in effective treatment and prevention measures. The Global Opioid Overdose Treatment Market is estimated to be valued at US$ 2.5 Billion in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024 to 2031. K...

  Market Overview Optic neuritis is a medical condition characterized by inflammation of the optic nerve. The inflammation leads to a sudden temporary vision loss or blurring in one or both the eyes. Major symptoms include eye pain, redness in the eye, partial or complete vision loss and blurred vision. Conventionally, steroids have been used for treating optic neuritis; however, novel targeted therapies are being explored. For instance, cladribine and rituximab have shown promising results in controlling the inflammation and damage to optic nerve tissues. The global optic neuritis treatment market is primarily driven by the growing prevalence of optic neuritis and MS. The Global optic neuritis treatment market is estimated to be valued at US$ 142 million in 2024 and is expected to exhibit a CAGR of 6.1% over the forecast period 2024-2032. Key Takeaways Key players operating in the optic neuritis treatment market are Novartis, Teva Pharmaceuticals, Bayer, Pfizer, Sanofi, Brist...

  Pediatric brain tumors refer to abnormal mass of cells in the brain, which affects children aged between 0-14 years. These tumors can either be benign or malignant. Some of the common types of pediatric brain tumors include medulloblastoma, glioma, and astrocytoma. The growth and development of pediatric brain tumors are different from adult brain tumors due to anatomical and physiological differences between children and adults. Treatment of pediatric brain tumors involve surgery, chemotherapy, radiation therapy based on the type, size and location of the tumor. Early diagnosis play a crucial role in improving the overall survival rates of pediatric brain tumors. The global pediatric brain tumors market is estimated to be valued at US$ 296.2 million in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024-2032. Increasing prevalence of pediatric brain tumors due to genetic factors and changing lifestyle is primarily driving the market growth. As per W...

  The peritoneal cancer market comprises of products such as chemotherapy drugs and equipment used to administer chemotherapy for peritoneal cancer treatment. Some key chemotherapy drugs used in peritoneal cancer treatment include cisplatin, carboplatin, paclitaxel, and bevacizumab. Equipment involved include elastomeric pumps, infusion systems, and catheters. Peritoneal cancers arise from the peritoneum, which is a thin layer of tissue that lines the inner wall of the abdomen and covers most of the abdominal organs. Peritoneal cancers are rare but aggressive types of cancer that affect the abdominal area. Early signs and symptoms are vague but may include abdominal pain, swelling in the abdomen, and weight loss. Advances in early detection through improved imaging technologies and minimally invasive surgical techniques have enabled faster diagnosis and treatment of peritoneal cancers. The Global peritoneal cancer therapeutics market is estimated to be valued at US$ 562 million ...

  Pheochromocytoma is a rare neuroendocrine tumor that affects the chromaffin cells of the adrenal medulla or extra-adrenal paraganglia. It can cause high blood pressure and other symptoms due to increased production of the stress hormones epinephrine and norepinephrine. The conventional treatment for pheochromocytoma includes surgical resection of the tumor along with preoperative preparation to manage blood pressure spikes during surgery. However, the recent development of novel targeted therapies such as radiolabeled MIBG therapy and tyrosine kinase inhibitors has provided more treatment options for advanced and metastatic pheochromocytoma. The global Pheochromocytoma Treatment Market is estimated to be valued at US$ 112 million in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2032. Key Takeaways Key players operating in the pheochromocytoma treatment market are Pfizer Inc., Bausch Health Companies Inc., Progenics Pharmaceuticals Inc., B...

  Market Overview Proliferative diabetic retinopathy (PDR) is a vision-threatening retinal complication of diabetes, where abnormal new blood vessels grow on the surface of the retina or in the clear, vitreous gel that fills the middle of the eye. The overall prevalence of diabetic retinopathy is estimated to be 35.4% amongst diabetics. Proliferative retinopathy develops due to long-term exposure of retinal tissues to high blood sugar levels, which results in damage to blood vessels in the retina. The key symptoms include blurred or diminished vision, dark or empty spots in the field of vision. In severe cases, it can even lead to vision loss. Retinal specialists usually diagnose and monitor PDR with eye exams and retinal photography or imaging tests. Laser photocoagulation treatment helps reduce the production of abnormal blood vessels. The Global Proliferative Diabetic Retinopathy Market is estimated to be valued at US$ 863 million in 2024 and is expected to exhibit a CAGR of...

  Propionic acidemia is an inherited genetic disorder that affects how the body breaks down certain protein-containing foods. It occurs due to the deficiency of an enzyme called propionyl-CoA carboxylase (PCC) that helps break down protein. As a result, toxic levels of propionic acid and ammonia build up in the body which can damage the nervous system resulting in poor muscle tone, seizures, intellectual disabilities and cardiac arrest if left untreated. Currently, treatment options are limited and focus on managing acute episodes and preventing long term complications through special diet, vitamin B12 injections, medication to lower ammonia levels and liver transplant. The global propionic acidemia therapeutics market is estimated to be valued at US$50 million in 2024 and is expected to exhibit a CAGR of 5% over the forecast period 2024-2032. Key Takeaways Key players operating in the propionic acidemia therapeutics market include Synlogic, Mirum Pharmaceuticals, Recordati...

  The Pseudomonas aeruginosa infection market is one of the key segments in the healthcare industry. Pseudomonas aeruginosa infections are common opportunistic infections in hospital settings that affect immunocompromised patients. The bacteria infect wounds, lungs of cystic fibrosis patients, and other areas of the body. With no vaccines available, treatment depends on antibiotics. However, P. aeruginosa has grown increasingly resistant to commonly used antibiotics over the years. Major products in the market include antibiotics such as piperacillin, cefepime, imipenem, meropenem, and ciprofloxacin that treat existing infections. Antibiotics are administered intravenously or inhaled for lung infections. The Global Pseudomonas aeruginosa infection treatment market is estimated to be valued at US$2.3 billion in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024-2029. Key Takeaways Key players operating in the Pseudomonas aeruginosa infection market ar...

  The Pyoderma Gangrenosum Treatment market has witnessed significant growth over the past few years owing to rising prevalence of inflammatory skin diseases. Pyoderma Gangrenosum is a rare form of neutrophilic dermatosis characterized by recurrent, painful cutaneous ulcerations that can be difficult to treat. The first line therapies for Pyoderma Gangrenosum treatment include systemic corticosteroids and immunosuppressants such as cyclosporine and azathioprine. However, a significant proportion of patients remain resistant or intolerant to conventional therapies, emphasizing the need for novel treatment strategies. Biologics such as anti-TNF alpha agents have shown promise in treatment of recalcitrant cases of Pyoderma Gangrenosum. The Global Pyoderma Gangrenosum Treatment Market is estimated to be valued at US$ 291.3 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the Pyoderma Gangrenosum Tr...